The Department of National Defence (DND) through the Strategic Medical Countermeasures Program on behalf of the Canadian Forces Health Services Group, has a requirement for Pralidoxime for the treatment of Canadian Armed Forces (CAF) members suspected of exposure to chemical warfare agents.
The initial requirement is for the delivery of 1,025 doses to be delivered before 31 March 2026. Optional requirements of 4,100 doses to be requested and delivered between 01 April 2026 and 31 March 2030.
There are no security requirements associated with this requirement.
The Crown retains the rights to negotiate with suppliers on any procurement.
Documents may be submitted in either official language of Canada.
Policy on Reciprocal Procurement: This solicitation of offers is open only to Canadian suppliers (if subject to any international trade agreement(s)): and to Suppliers of an applicable trading partner.